Palladium-Item

Alume Delivers Positive Topline Results for Bevonescein, a Potential First-in-Class Surgical Nerve Visualization Drug

Alume Biosciences delivers positive topline results for three pivotal trials of Bevonescein, advancing toward NDA submission with US FDA in 2H 2026 Even with meticulous technique, surgeons are limited ...
Morningstar

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) ...
Business Insider

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of ...
Healio

FDA clears investigational new drug application for ER-100

Please provide your email address to receive an email when new articles are posted on . ER-100 is the first cellular rejuvenation therapy to receive clearance for human clinical trials. A phase 1 ...